alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 726–750 of 1,246 studies (page 30 of 50) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 1,246 studies tagged prevalence — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Co-calibration of cognitive performance in the National Health and Aging Trends Study with the Health and Retirement Study's Harmonized Cognitive Assessment Protocol: Implications for dementia classification

✓ Peer-reviewed alzhub usefulness score 45 out of 100. SSM - Population Health 2025-04-06

Study-specific algorithms yielded comparable dementia prevalence estimates: 10.8 % in NHATS and 11.1 % in HRS-HCAP. 5 key findings →

Participants: 5,696 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Reliability and validity analysis of the Chinese version of the Quick Dementia Rating System (QDRS)

✓ Peer-reviewed alzhub usefulness score 45 out of 100. BMC Geriatrics 2025-07-02

/df = 2.81, P < 0.001). There were strong correlations between the C-QDRS and standardized neuropsychological tests, indicating that the C-QDRS exhibited concurrent validity (all P < 0.001). 4 key findings →

Participants: 366 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A vision transformer approach for fully automated and scalable dementia screening using clock drawing test images

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-07-01

The ViT approach predicted dementia with 76.5% balanced accuracy, outperforming human-scored features (74.3%) and existing deep learning models (MiniVGG = 73.3%, MobileNetV2 = 72.3%, relevance factor variational autoencoder = 69.1%) on the TDRA dataset. 3 key findings →

Participants: 862 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroimaging markers of dementia across race/ethnicity and sex/gender using an intersectional approach within the HABS‐HD cohort

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-09-01

We analyzed data from 3433 dementia-free participants with either magnetic resonance imaging or positron emission tomography (PET) data at baseline (mean [standard deviation] age: 65 [9] years, 36% non-Hispanic White [NHW], 27% Black, 37% Hispanic, and 63% women). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

FUNCTIONAL OUTCOME IN HOME HEALTH AMONG TRADITIONAL MEDICARE AND MEDICARE ADVANTAGE BENEFICIARIES WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Innovation in Aging 2024

This study examines the difference in functional outcomes among Traditional Medicare (TM) and Medicare Advantage (MA) beneficiaries with Alzheimer’s disease and related dementias (ADRD) during a home health admission, which is unknown. 5 key findings →

Design: cohort study Participants: 81,735 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Psychosocial interventions for people with dementia: An overview and commentary on recent developments

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Dementia (London, England) 2016-07-04

An influential review in 2010 concluded that non-pharmacological multi-component interventions have positive effects on cognitive functioning, activities of daily living, behaviour and mood of people with dementia. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of the American Geriatrics Society 1999-04-01

GMHR is a reliable, valid, global bedside measure of severity of general medical comorbidity for patients with dementia that can be used for clinical and research purposes. 1 key finding →

Participants: 819 Evidence: low

Full summary, score breakdown and related studies → Original source

Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Archives of neurology 1997-06-01

Dementia adversely affects driving performance even in its mild stages, although some persons with DAT seem to drive safely for some time after disease onset. 1 key finding →

Participants: 123 Evidence: low

Full summary, score breakdown and related studies → Original source

Different cognitive profiles for single compared with recurrent fallers without dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neuropsychology 2009-07-01

Relationships between self-reported retrospective falls and cognitive measures (executive function, reaction time [RT], processing speed, working memory, visual attention) were examined in a population based sample of older adults (n = 658). 1 key finding →

Participants: 658 Evidence: low

Full summary, score breakdown and related studies → Original source

Variation in Medicare Part D and Part B drug spending among older adults with Alzheimer's disease and related dementias

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Innovation in Aging 2026-08-03

Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions. 1 key finding →

Design: cross-sectional Participants: 1,372,696 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

9 of the 1,233 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed